In many ways, 2017 was a “wait-and-see” year for biopharma as a new administration entered the White House. The industry came under fire early when President-elect Donald Trump said it was “getting away with murder” on pricing. More than a year later, biopharma has been spared real reform, and that’s reflected in overall revenues. Which pharma companies wound up on top?